➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Dow
McKesson
McKinsey
Boehringer Ingelheim

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

SONATA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Sonata patents expire, and what generic alternatives are available?

Sonata is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in SONATA is zaleplon. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the zaleplon profile page.

US ANDA Litigation and Generic Entry Outlook for Sonata

A generic version of SONATA was approved as zaleplon by AUROBINDO PHARMA on June 6th, 2008.

  Start Trial

Paragraph IV (Patent) Challenges for SONATA
Tradename Dosage Ingredient NDA Submissiondate
SONATA CAPSULE;ORAL zaleplon 020859 2005-06-21

US Patents and Regulatory Information for SONATA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer SONATA zaleplon CAPSULE;ORAL 020859-001 Aug 13, 1999 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer SONATA zaleplon CAPSULE;ORAL 020859-002 Aug 13, 1999 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for SONATA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0208846 SPC/GB99/024 United Kingdom   Start Trial PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312
0208846 C990021 Netherlands   Start Trial PRODUCT NAME: ZALEPLONUM; REGISTRATION NO/DATE: EU/1/99/099/001 - EU/1/99/099/006, EU/1/99/102/001 - EU/1/99/102/006 19990312
0208846 99C0032 Belgium   Start Trial PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: NL 24 551 19990726; FIRST REGISTRATION: SE - 14 997 19990209
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Dow
McKesson
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.